Operating
Biogen·Cash Flow Statement·19 metrics
Breakdown
| Metric | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Net cash from operating activities | $625.8M | $935.6M | $760.9M | $259.3M | $160.9M | $1.3B | $511.9M | $645.5M |
| Net income | $583.6M | $388.5M | $266.7M | $240.5M | $634.8M | $466.5M | $0 | $319.5M |
| Change in accrued liabilities | — | — | $108.8M | -$300.5M | -$18.2M | $286M | $203.8M | -$243.2M |
| Depreciation and amortization | $158.9M | $182.8M | $184M | $183.2M | $194.3M | $202.2M | $200.2M | $204.4M |
| Change in inventories | $110.5M | $19.2M | $66.4M | -$62M | $89.9M | $7.4M | $29.4M | -$116.2M |
| Amortization of acquired inventory step-up | $90.1M | $50.9M | $44.9M | $51.4M | $52.5M | $61.5M | $75.4M | $107.6M |
| Other working capital changes | $46.9M | — | — | $53.5M | $22M | $104.4M | — | $89M |
| Stock-based compensation | $70.6M | $72.7M | $75.1M | $81M | $74.9M | $75.3M | $59.6M | $84M |
| Other Noncash Income (Expense) | -$39.6M | -$30.1M | -$64.5M | -$6.7M | -$9.3M | -$33.3M | -$19M | -$28M |
| Deferred income taxes | -$87M | -$52.6M | -$58.4M | -$27.8M | -$31.3M | $253.8M | $166.9M | $23.6M |
| Change in fair value of contingent consideration | $0 | $23.8M | — | $9.6M | $13.2M | $5.6M | — | $20.5M |
| Contingent consideration fair value adjustments | $0 | $23.8M | — | $9.6M | $13.2M | $5.6M | — | $20.5M |
| Net gains (losses) on investments | -$30.3M | — | -$78.7M | -$40.9M | — | -$500K | — | $19M |
| Change in income taxes payable/receivable | -$5.5M | $69.8M | $16.4M | $69.1M | -$603.8M | -$229.4M | -$194M | $18.4M |
| Inventory write-downs | $16.9M | $24.3M | $33.2M | $7.3M | $7M | $0 | $15.3M | $4.8M |
| Change in accounts receivable | -$55.6M | -$55.6M | -$55.6M | -$25.7M | -$25.7M | -$25.7M | -$25.7M | — |
| Change in other liabilities | -$44.7M | -$44.7M | -$44.7M | -$62M | -$62M | -$62M | -$62M | — |
| Lease impairment charges | $0 | $0 | $0 | $13.2M | $13.2M | $13.2M | $13.2M | — |
| Acquired in-process research and development | $0 | $0 | $0 | $21.3M | $21.3M | $21.3M | $21.3M | — |